StockData
Immatics N.V. logo

Immatics N.V. (IMTX) stock

IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$6.17−0.22 (-3.44%)

Close on Nov 16, 2026Market cap $827.22MP/E –Yield –

Immatics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €183.83M, up 24.1% from the year before. The highest annual figure on record is €183.83M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€183.83M+24.1%
FY2024Dec 31, 2024€148.08M+24.8%
FY2023Dec 31, 2023€118.66M+11.1%
FY2022Dec 31, 2022€106.78M+21.9%
FY2021Dec 31, 2021€87.57M+30.5%
FY2020Dec 31, 2020€67.09M+67.3%
FY2019Dec 31, 2019€40.09M+18.0%
FY2018Dec 31, 2018€33.97M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€62.41M+147.5%
Q2 FY2025Jun 30, 2025€45.11M+121.8%
Q2 FY2024Jun 30, 2024€35.22M+113.4%
Q2 FY2023Jun 30, 2023€27.32M–
Q2 FY2022Jun 30, 2022€25.22M–
Q2 FY2021Jun 30, 2021€20.34M–
Q2 FY2020Jun 30, 2020€16.51M–

More Immatics figures

See a number that looks wrong?